Roche’s Genentech Doubles North Carolina Facility Investment to About $2 Billion

Genentech, a unit of Roche, said it will more than double its planned investment in a biomanufacturing facility in North Carolina to about $2 billion, reinforcing its commitment to expanding production in the United States.

The facility, located in Holly Springs, North Carolina, is expected to become operational by 2029 and will focus on manufacturing next-generation treatments for metabolic conditions, including obesity. Genentech said the expanded investment will significantly increase production volumes and manufacturing capacity at the site.

The project is expected to support more than 2,000 jobs, including around 500 high-wage manufacturing roles and approximately 1,500 construction jobs. The expansion builds on an initial investment of more than $700 million announced in May last year, as the company sought to strengthen its U.S. footprint.

The move aligns with broader efforts by major pharmaceutical companies to boost domestic manufacturing, amid calls from U.S. President Donald Trump for drugmakers to onshore more production. Roche and Genentech have said the investment forms part of a wider $50 billion commitment to the U.S. market.